Catalent to increase patient-centric dose form manufacturing capabilities at Winchester, Kentucky

6 May 2019

$40 million investment adds spray drying, stick pack and expanded capabilities in controlled-release tableting and encapsulation.

Catalent is investing up to $40 million at its manufacturing facility in Winchester, Kentucky. The investment will see the installation of new equipment that will increase the site’s formulation and controlled-release tablet and capsule manufacturing capabilities, and capacity.

Catalent to increase patient-centric dose form manufacturing capabilities at Winchester, Kentucky

New technologies that are included in the investment include a laser drill for osmotic drug delivery, stick pack dosage manufacturing capabilities, and roller compaction and fluid bed capacity will be increased at the site. In addition, a spray dryer, used to create amorphous solid dispersions and overcome formulation challenges posed by poorly soluble drugs, will be installed to provide commercial scale up capacity for projects that progress from early-stage development, and allow tech transfer of projects from Catalent’s development sites including San Diego and Nottingham, UK.

An automated bottling line is also currently being installed, and completion of the various equipment validations is expected over the coming months.

“Our Winchester facility provides customers with a high degree of flexible manufacturing solutions and has a proven track record of success with technology transfers and product launches,” commented Rick Tucker, General Manager, Catalent Winchester. “We have a clear investment strategy at the site that is not only driven by immediate customer needs, but also looks to the future in anticipation of demand and new technologies.”

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more